Company profiles


Sanofi Genzyme 500 Kendall Street, Cambridge, MA 02142 USA Contact person: Bo Piela VP Media Relations Web: www.genzyme.com	Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at www.sanofigenzyme.com .


AbbVie Inc. 1 N Waukegan Rd North Chicago, Illinois 60064-1802 United States Phone number: (847) 932-7900 abbvie.com	AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2015, AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbVie on Twitter.
	Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. In addition, Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Further information about Alexion can be found at www.alexion.com.
200 Longwater Avenue, Green Park, Reading, Berkshire RG2 6GP T: +44 1189209500	Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specializing in niche innovative products for chronic and serious medical conditions, and in particular, the treatment of patients with Parkinson's disease. The need for apomorphine as a treatment option for Parkinson's disease has led to the development of APO-go and other associated brands around the globe, which are available in many countries through our Distribution or Licensing Partners. For more information please visit www.britannia-pharm.comor www.apo-go.com
Cynapsus Therapeutics Inc. \|828 Richmond Street West, Toronto, Ontario, M6J 1C9, Canada \| T: 416.703.2449\|F: 647.260.2010 \| http://www.cynapsus.ca/	Cynapsus Therapeutics is a specialty pharmaceutical company that is focused on the clinical and regulatory development of a sublingual apomorphine film strip (APL-130277), for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease (PD). The Company recently completed a Phase 2 clinical trial for APL-130277. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States, Europe, Japan and other countries. Cynapsus' drug candidate, APL-130277, is a sublingual form of apomorphine that is currently enrolling patients in Phase III clinical studies (clinicaltrials.gov: NCT02469090 and NCT02542696). Cynapsus intends to submit a new drug application in 2016.
4 Parkway North Deerfield, IL USA 60015 Phone: 847-282-1000 Fax: 847-282-1001 Lundbeck.com	Lundbeck is a global pharmaceutical company specialized in brain disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and symptomatic neurogenic orthostatic hypotension (NOH). In the U.S., Lundbeck employs more than 800 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in hundreds of initiatives each year that support our patient communities. To learn more, visit us at www.LundbeckUS.com and connect with us on Twitter at @LundbeckUS.
Merck KGaA \| Frankfurter Str. 250 \| Postcode: F135/101 \| 64293 Darmstadt \| Germany E-mail: globalmeded@merckgroup.com \| www.merck.de Mandatory information can be found at http://mandatories.merckgroup.com	Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

BIAL Headquarters: Address: À Avenida da Siderurgia Nacional - 4745-457 Coronado (S. Romão e S. Mamede) - Portugal Phone: + 351 22 986 6100 Email: info@bial.com Site: www.bial.com	BIAL is an international pharmaceutical company strongly committed to innovation. Founded in 1924, BIAL's mission is to discover, develop and provide new therapeutic solutions. Consistently investing more than 20% of its turnover in Research and Development (R&D), BIAL has established an ambitious R&D program centred on the central nervous, cardiovascular system and allergy immunotherapy. The company has developed an antiepileptic drug, (Zebinix - eslicarbazepine acetate) already commercialized in the US market and in several European countries. A second compound from its R&D pipeline for the treatment of Parkinson's disease, Opicapone, is under review by the European Medicines Agency.
Daiichi Sankyo Europe GmbH ⋅ Zielstattstr. 48 ⋅ 81379 Munich ⋅ Germany Phone +49 89 78080 ⋅ Fax +49 89 7808267 www.daiichi-sankyo.eu	About Daiichi Sankyo Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com About Daiichi Sankyo Europe Daiichi Sankyo's European base is located in Munich and has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: www.daiichi-sankyo.eu
Address: Grenzacherstrasse 124, 4070 Basel, Switzerland Phone:+41 61 688 11 11	Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com .
Teva Pharmaceuticals 11100 Nall Ave, Overland Park, KS 66211 (800) 221-4026 http://www.tevapharm.com/	Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs and innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory, oncology, pain, and women's health therapeutic areas as well as biologics. Teva employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.

Muellerstr. 178 13353 Berlin Germany Tel: +49-30-468-1111	Bayer: Science For A Better Life Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

electroCore LLC 150 Allen Road, Suite 201 Basking Ridge, NJ 07920 Phone: +1.973.290.0097 Fax: +1.973.2909171 www.electrocorellc.com	Leading the world of electroceuticals by developing therapies that directly, and non-invasively, target nerve signal imbalances and restore normal neurological function to help patients live life to its fullest, electroCore LLC is a U.S. based healthcare company developing non-invasive Vagus Nerve Stimulation (nVNS) therapies for the treatment of multiple conditions. The gammaCore® is the first of its kind, hand-held device that uses proprietary electrical signals to treat primary headache disorders.
Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 U.S.A. +1.317.276.2000 Web: www.lilly.com	For 139 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.
One MedImmune Way, Gaithersburg, MD 20878, USA; 301 398-0000; www.MedImmune.com	MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centers, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.
MSD Kenilworth, NJ 07033 USA http://www.merck.com/	Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit http://www.merck.com/ and connect with us on Twitter, Facebook and YouTube.
Neuropore Therapies, Inc. 10835 Road to the Cure, Suite 210 San Diego, CA 92121 USA Phone: +1-858-273-1831 Fax: +1-858-273-1839 Email: info@neuropore.com URL: www.neuropore.com	Neuropore Therapies, Inc. is a biopharmaceutical company founded in 2008 by Professor Eliezer Masliah and colleagues from University of California at San Diego. We are committed to the discovery and development of disease modifying treatments for Parkinson's Disease, Alzheimer's Disease, and other neuro-degenerative disorders. Based in San Diego, global collaborations with academia and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics. Our ultimate goal is to improve the lives of patients and their families by providing medicines that will slow, stop, or revert the progression of their disease.
Takeda Pharmaceuticals International GmbH Singapore Branch 21 Biopolis Road, #04-24/28 Nucleos South Tower, Singapore 138567	Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

157 Church Street, 19th Floor New Haven, Connecticut 06510 USA www.bioblast-pharma.com Phone: 475-655-3032	Founded in 2012 BioBlast Pharma is a publicly traded, clinical stage biopharmaceutical company developing novel, first-in-class disease modifying therapies to treat the underlying causes of rare genetic neurological diseases with high unmet medical need. Through a deeper understanding of disease-causing biological mechanisms, the company is building a robust pipeline of investigational new therapies. The company's lead clinical drug candidate (trehalose 90mg/mL IV solution) is in Phase 2 development. Trehalose 90mg/mL IV solution would be a first-in-class and first therapeutic to potentially treat a number of devastating PolyA/PolyQ diseases, including its two lead indications of oculopharyngeal muscular dystrophy (OPMD) and spinocerebellar ataxia type 3 (SCA3).
Edif. Bluepharma, Rua da Bayer, 3045-016 Coimbra – Portugal Phone: +351 239 800 300 E-mail: bluepharma@bluepharma.pt Website: http://www.bluepharmagroup.com/	Bluepharma is a privately owned pharmaceutical company, based in Coimbra, Portugal. Bluepharma Group currently comprises more than 15 innovative affiliates that cover all stages of the pharmaceutical industry value chain. Bluepharma's R&D-based strategy allowed to target the most demanding markets of over 40 worldwide territories, representing more than 100 clients and an export rate of 86% Its mission is to market pharmaceutical products of the highest quality at competitive prices, contributing for the rationalization of expenses in the health sector and simultaneously to the improvement of the life quality of populations. For more information, please visit: www.bluepharmagroup.com
Av. D. Carlos I, 126 1249-074 Lisboa, Portugal Tel: +351 213 924 300 Fax: +351 213 956 519 Email: facc@fct.pt	Fundação para a Ciência e a Tecnologia (FCT) is the Portuguese national funding agency that supports science, technology and innovation, in all scientific domains, under responsibility of the Ministry for Science, Technology and Higher Education. FCT's mission is to continuously promote the advancement of knowledge in science and technology in Portugal, attain the highest international standards in quality and competitiveness, in all scientific and technological domains, and encourage its dissemination and active role in society and in economic growth.
5 Nachum Heth St., POB 2059 Tirat Carmel, 3912001, Israel Tel: 972-4-8131313 http://www.insightec.com/	Powered by over 100 patents and winner of numerous technology awards, INSIGHTEC is the global leader in MR-guided Focused Ultrasound (MRgFUS) neurosurgery and developer of the ExAblate Neuro platform. The first company to successfully steer and focus ultrasound through the cranium, the ExAblate Neuro is presently an Investigational Device undergoing FDA clinical evaluation in the US and has a CE mark for essential tremor, Parkinsonian tremor and neuropathic pain. INSIGHTEC is actively pursuing research and development to expand the applications for its technology with a goal of becoming a non-invasive standard of care in medicine.
VIVISOL Postbus 4270 5004JG Tilburg, Nederland Telephone +31 (0) 13 5231020 Fax +31 (0) 13 5231029 Email info@vivisol.nl URL http://www.vivisol.nl/ / http://www.vivisol.com/	VIVISOL is one of the premier European groups working in the home care sector, specialised in respiratory care, (in particular diagnosis, care of OSAS, oxygen therapy, mechanical ventilation) and also provide services in the fields of woundcare and telemedicine. VIVISOL constantly focusses on developing, evolving and refining our respiratory care solutions through evaluation, assessment and comparison of the different options available in the healthcare sector. We aim to provide patients with the best service possible. Hence, VIVISOL focuses on "IMPROVING THE QUALITY OF LIFE" of chronic patients, whose therapy is delivered at home or in comfortable residential facilities.

Wisepress Medical Bookshop 25 High Path, Merton Abbey, London, SW19 2JL UK Phone: +44 20 8715 1812 Fax: +44 20 8715 1722 marketing@wisepress.com www.wisepress.com	Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
Zambon S.p.A. Bresso (Milano), via Lillo del Duca 10 - 20091 Bresso (MI-Italy). Direct: +39-0266524265 Fax: +39-0266524844 www.zambongroup.com	Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care, and is very strongly committed to its entry into the CNS space. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. The Group is strongly working on the treatment of the chronic respiratory diseases as asthma and COPD and on the CNS therapeutic area with Xadago® (safinamide) for the Parkinson treatment. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries and more than 2,600 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries.